Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $19.4 (market cap $60.06B), while Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) trades at $8.59 (market cap $9.09B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 6.6× Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares)'s market cap, and Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) pays the higher dividend (3.84%). Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 6 Days and Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) for 0 Days on average.
| TAK | YMM | |
|---|---|---|
Market Cap | $60.06B | $9.09B |
Volume | 2,925,042 | 10,124,674 |
Sector | Health | Technology |
52-Week High | $19.05 | $13.30 |
52-Week Low | $13.23 | $7.54 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $87.89B | $5.57B |
Dividend Yield | 3.33% | 3.84% |
Signals from Pluang's Aura AI — not financial advice
TAK trades at $18.52, down 0.86% on the day. The stock shows mixed signals with a bullish technical outlook from moving averages but neutral oscillators. Recent financials reveal a net income margin of -3.54% for 2026, though revenue remains stable near $4.6 trillion. Positive developments include the launch of ORZEYFUL for narcolepsy and FDA priority review for zasocitinib, highlighting a robust pipeline. Cash flow improved to $209.8 billion in 2026 from a negative position in 2025.
Outlook: TAK's strong analyst support (83% buy ratings) and promising drug pipeline offer growth potential, but profitability concerns and high P/E of 51.56 pose risks. Investors should weigh pipeline successes against current negative margins and elevated valuation.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →Full Truck Alliance Co. Ltd. operates a digital freight-matching platform in China, connecting shippers with truckers for cargo transport across varying distances and load types.
Read more on YMM →